Hospital Vila Nova Star - ICU and Critical Care Nephrology Department, Rua Dr. Alceu de Campos Rodrigues 126, São Paulo, Brazil.
Instituto D'Or de Pesquisa e Ensino, Avenida República do Líbano 611, São Paulo, Brazil.
BMC Nephrol. 2023 Mar 2;24(1):46. doi: 10.1186/s12882-023-03095-4.
Acute Kidney Injury (AKI) in COVID-19 patients is associated with increased morbidity and mortality. In the present study, we aimed to develop a prognostic score to predict AKI development in these patients.
This was a retrospective observational study of 2334 COVID 19 patients admitted to 23 different hospitals in Brazil, between January 10th and August 30rd, 2020. The primary outcome of AKI was defined as any increase in serum creatinine (SCr) by 0.3 mg/dL within 48 h or a change in SCr by ≥ 1.5 times of baseline within 1 week, based on Kidney Disease Improving Global Outcomes (KDIGO) guidelines. All patients aged ≥ 18 y/o admitted with confirmed SARS-COV-2 infection were included. Discrimination of variables was calculated by the Receiver Operator Characteristic Curve (ROC curve) utilizing area under curve. Some continuous variables were categorized through ROC curve. The cutoff points were calculated using the value with the best sensitivity and specificity.
A total of 1131 patients with COVID-19 admitted to the ICU were included. Patients mean age was 52 ± 15,8 y/o., with a prevalence of males 60% (n = 678). The risk of AKI was 33% (n = 376), 78% (n = 293) of which did not require dialysis. Overall mortality was 11% (n = 127), while for AKI patients, mortality rate was 21% (n = 80). Variables selected for the logistic regression model and inclusion in the final prognostic score were the following: age, diabetes, ACEis, ARBs, chronic kidney disease and hypertension.
AKI development in COVID 19 patients is accurately predicted by common clinical variables, allowing early interventions to attenuate the impact of AKI in these patients.
COVID-19 患者的急性肾损伤(AKI)与发病率和死亡率增加有关。在本研究中,我们旨在开发一种预测评分来预测这些患者的 AKI 发展。
这是一项回顾性观察研究,纳入了 2020 年 1 月 10 日至 8 月 30 日期间在巴西 23 家不同医院就诊的 2334 名 COVID-19 患者。AKI 的主要结局定义为 48 小时内血清肌酐(SCr)升高 0.3mg/dL 或 1 周内 SCr 变化≥基线的 1.5 倍,基于肾脏疾病改善全球结局(KDIGO)指南。所有年龄≥18 岁并确诊 SARS-COV-2 感染的患者均被纳入。通过接收者操作特征曲线(ROC 曲线)计算变量的判别能力,利用曲线下面积。一些连续变量通过 ROC 曲线进行分类。使用具有最佳灵敏度和特异性的价值计算截断点。
共纳入 1131 例 COVID-19 患者入住 ICU。患者平均年龄为 52±15.8 岁,男性患病率为 60%(n=678)。AKI 的风险为 33%(n=376),其中 78%(n=293)无需透析。总死亡率为 11%(n=127),而 AKI 患者的死亡率为 21%(n=80)。选择用于逻辑回归模型的变量和纳入最终预测评分的变量如下:年龄、糖尿病、ACEis、ARBs、慢性肾脏病和高血压。
COVID-19 患者 AKI 的发展可以通过常见的临床变量准确预测,从而可以进行早期干预来减轻 AKI 对这些患者的影响。